US Treasury Drafts Pharma China Investment Rules
Analysis based on 7 articles · First reported Sep 18, 2026 · Last updated Sep 18, 2026
The rules would preserve billions of dollars in US-China pharmaceutical licensing deals, supporting valuations for US drugmakers like Pfizer and Bristol Myers Squibb and providing capital to Chinese biotech firms such as Jiangsu Hengrui and Innovent Biologics. Uncertainty remains as the rules are not finalized and face opposition from lawmakers and smaller biotech companies, which could introduce volatility in the sector.
The United States — United States Department of the Treasury is drafting rules governing US pharmaceutical companies' investments in China that would likely preserve their ability to strike most licensing deals for Chinese drugs, according to three people briefed on the process. The rules would allow investment in promising new drugs developed by Chinese companies as long as they are not related to pathogens or weaponizable biotechnology. This approach departs from the Trump administration's tightening of business with China in other industries under new national security legislation and is looser than restrictions sought by some lawmakers. The rules have not been finalized and could change, particularly if Donald Trump weighs in. Pfizer and other major drugmakers have lobbied against broad restrictions, arguing they would cut US companies off from a fast-growing source of new medicines. Pfizer CEO Albert Bourla said he discussed China and national security concerns with Scott Bessent, Marco Rubio and representatives of the United States — United States Department of Health and Human Services. Smaller biotech firms including Ginkgo Bioworks and its CEO Jason Kelly have advocated for restrictions, warning of strategic dependence on China. Lawmakers John Moolenaar and Debbie Dingell are co-sponsoring a bill for tighter Treasury regulation of biotechnology-related investments, licensing agreements and joint ventures involving Chinese companies. Jake Auchincloss opposes curbing US spending in the sector. Outside licensing deals in Chinese biotech were worth $115 billion last year, according to GlobalData. Xi Jinping is due to meet with Trump in the US next week, and Treasury is unlikely to unveil new rules before that meeting.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard